Cytochrome P450 1A2 (CYP1A2) Genotyping
Cytochrome P450 1A2 (CYP1A2)
Whole blood or buccal swabs
5 mL of whole blood or four buccal swabs
3 mL of whole blood or four buccal swabs
Lavender-stopper (EDTA) tube or paper envelope for dried buccal swabs
Maintain at room temperature or refrigerate
Cause for Rejection
Hemolyzed specimen; quantity not sufficient
General Purpose and Use
CYP1A2 metabolizes many medications, including theophylline, diazepam, caffeine, and amitriptyline. CYP1A2 can be induced by several medications, substrates, and constituents of tobacco smoke. CYP1A2 can also be inhibited by several medications. Basal metabolic capacity remains relatively consistent among the different genotypes in the absence of an inducer. Detecting variants of the CYP1A2 gene that cause altered enzymatic induction in the presence of an inducer can identify patients who may be at increased risk of having adverse drug reactions or therapeutic failure to standard dosages of CYP1A2 substrates.
CYP1A2*1A, *1C, *1E, *1F, *1J, *1K, *1L
Other variants of the CYP1A2 gene that are not detected in this assay may influence drug metabolism. CYP1A2 metabolic capacity is also influenced by concomitant medications, inhibitors, inducers, diet and various disease states. All factors should be considered as part of the overall patient management strategy.
Real-time polymerase chain reaction with fluorescence detection.
For a PDF version, click here.